1d6e: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|PDB= 1d6e |SIZE=350|CAPTION= <scene name='initialview01'>1d6e</scene>, resolution 2.45Å | |PDB= 1d6e |SIZE=350|CAPTION= <scene name='initialview01'>1d6e</scene>, resolution 2.45Å | ||
|SITE= | |SITE= | ||
|LIGAND= <scene name='pdbligand=ACE:ACETYL GROUP'>ACE</scene> | |LIGAND= <scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene>, <scene name='pdbligand=ALC:2-AMINO-3-CYCLOHEXYL-PROPIONIC+ACID'>ALC</scene>, <scene name='pdbligand=BUG:TERT-LEUCYL+AMINE'>BUG</scene>, <scene name='pdbligand=MPQ:N-METHYL-ALPHA-PHENYL-GLYCINE'>MPQ</scene> | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
|DOMAIN= | |||
|RELATEDENTRY=[[1d5m|1D5M]], [[1d5x|1D5X]], [[1d5z|1D5Z]] | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1d6e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1d6e OCA], [http://www.ebi.ac.uk/pdbsum/1d6e PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1d6e RCSB]</span> | |||
}} | }} | ||
| Line 26: | Line 29: | ||
[[Category: Kammlott, U.]] | [[Category: Kammlott, U.]] | ||
[[Category: Swain, A.]] | [[Category: Swain, A.]] | ||
[[Category: complex (mhc class ii/superantigen)]] | [[Category: complex (mhc class ii/superantigen)]] | ||
[[Category: immune system]] | [[Category: immune system]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 19:35:35 2008'' | ||
Revision as of 19:35, 30 March 2008
| |||||||
| , resolution 2.45Å | |||||||
|---|---|---|---|---|---|---|---|
| Ligands: | , , , | ||||||
| Related: | 1D5M, 1D5X, 1D5Z
| ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
CRYSTAL STRUCTURE OF HLA-DR4 COMPLEX WITH PEPTIDOMIMETIC AND SEB
OverviewOverview
Molecular features of ligand binding to MHC class II HLA-DR molecules have been elucidated through a combination of peptide structure-activity studies and structure-based drug design, resulting in analogues with nanomolar affinity in binding assays. Stabilization of lead compounds against cathepsin B cleavage by N-methylation of noncritical backbone NH groups or by dipeptide mimetic substitutions has generated analogues that compete effectively against protein antigens in cellular assays, resulting in inhibition of T-cell proliferation. Crystal structures of four ternary complexes of different peptide mimetics with the rheumatoid arthritis-linked MHC DRB10401 and the bacterial superantigen SEB have been obtained. Peptide-sugar hybrids have also been identified using a structure-based design approach in which the sugar residue replaces a dipeptide. These studies illustrate the complementary roles played by phage display library methods, peptide analogue SAR, peptide mimetics substitutions, and structure-based drug design in the discovery of inhibitors of antigen presentation by MHC class II HLA-DR molecules.
About this StructureAbout this Structure
1D6E is a Protein complex structure of sequences from Homo sapiens and Staphylococcus aureus. Full crystallographic information is available from OCA.
ReferenceReference
Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures., Bolin DR, Swain AL, Sarabu R, Berthel SJ, Gillespie P, Huby NJ, Makofske R, Orzechowski L, Perrotta A, Toth K, Cooper JP, Jiang N, Falcioni F, Campbell R, Cox D, Gaizband D, Belunis CJ, Vidovic D, Ito K, Crowther R, Kammlott U, Zhang X, Palermo R, Weber D, Guenot J, Nagy Z, Olson GL, J Med Chem. 2000 Jun 1;43(11):2135-48. PMID:10841792
Page seeded by OCA on Sun Mar 30 19:35:35 2008